These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 25483023

  • 21. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 22. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
    Malek R, Arbouche Z, Bachaoui M, Zinai S, Dahaoui A, Senoussaoui S, Salah-Mansour A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.
    Yang W, Ersoy C, Wang G, Ye S, Liu J, Miao H, Asirvatham A, Werther S, Kadu P, Chow F.
    Diabetes Res Clin Pract; 2019 Apr; 150():158-166. PubMed ID: 30872064
    [Abstract] [Full Text] [Related]

  • 24. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
    Balaji V, Balaji MS, Alexander C, Srinivasan A, Suganthi SR, Thiyagarajah A, Seshiah V.
    Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T.
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [Abstract] [Full Text] [Related]

  • 26. Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.
    Shanmugasundar G, Bhansali A, Walia R, Dutta P, Upreti V.
    Indian J Med Res; 2012 May; 135(1):78-83. PubMed ID: 22382187
    [Abstract] [Full Text] [Related]

  • 27. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L, Chen L, Chang B, Yang L, Liu Y, Feng B.
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [Abstract] [Full Text] [Related]

  • 28. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
    El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.
    Diabetes Res Clin Pract; 2012 Dec; 98(3):408-13. PubMed ID: 23217267
    [Abstract] [Full Text] [Related]

  • 29. Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.
    Banerjee S, Maji D, Baruah M.
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):24-7. PubMed ID: 24482984
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration.
    Gao Y, Luquez C, Lynggaard H, Andersen H, Saboo B.
    Curr Med Res Opin; 2014 Dec; 30(12):2483-92. PubMed ID: 25180608
    [Abstract] [Full Text] [Related]

  • 33. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [Abstract] [Full Text] [Related]

  • 34. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve).
    Shah S, Yang W, Hasan MI, Malek R, Molskov Bech O, Home P.
    Diabetes Technol Ther; 2013 Nov; 15(11):954-63. PubMed ID: 24053450
    [Abstract] [Full Text] [Related]

  • 35. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
    Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW.
    Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
    [Abstract] [Full Text] [Related]

  • 38. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
    Davies M, Sasaki T, Gross JL, Bantwal G, Ono Y, Nishida T, Tojjar D, Seino H.
    Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
    [Abstract] [Full Text] [Related]

  • 39. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.
    Herrera KM, Rosenn BM, Foroutan J, Bimson BE, Al Ibraheemi Z, Moshier EL, Brustman LE.
    Am J Obstet Gynecol; 2015 Sep; 213(3):426.e1-7. PubMed ID: 26070699
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.